A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD ...
Michael Jackson was involved in a Pepsi commercial accident in 1984. Here’s what to know about the incident that was depicted ...
Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...
Zacks Small Cap Research on MSN
LGND: XOMA buy adds 100+ assets
By John Vandermosten, CFA NASDAQ: LGND | NASDAQ: XOMA In an April 27th press release, Ligand Pharmaceuticals, Inc. (NASDAQ: ...
Some patients are being forced off their GLP-1 medication after losing insurance coverage. (NPR) Meanwhile, the Centers for ...
An update from Ligand Pharma ( (LGND)) is now available. On April 27, 2026, Ligand Pharmaceuticals agreed to acquire fellow royalty aggregator XOMA Royalty Corporation for $39.00 per share in cash, ...
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the ...
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal ...
A massive, nearly 20-year study tracking over 650,000 Americans with irritable bowel syndrome is raising new questions about the long-term safety of common treatments. Researchers found that some ...
Some vaccines, along with heart medications and other drugs, appear to have a protective benefit. By Dana G. Smith Getting your annual flu shot may come with a significant side benefit: helping to ...
Johnson & Johnson beat first-quarter earnings expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results